Brand Waali Quality, Bazaar Waali Deal!
Our Blog
Help Center
Sell On Snapdeal
Download App
Cart
Sign In

Sorry! Antiarrhythmic Drugs is sold out.

Compare Products
Clear All
Let's Compare!

Antiarrhythmic Drugs

This product has been sold out

pay
Rs  5,532
We will let you know when in stock
notify me

Highlights

  • ISBN10:3642856268
  • ISBN13:9783642856266
  • Publisher:Springer
  • Language:English
  • Binding:Paperback
  • SUPC: SDL433629775

Other Specifications

Other Details
Country of Origin or Manufacture or Assembly India
Common or Generic Name of the commodity Allied Health Services Books
Manufacturer's Name & Address
Packer's Name & Address
Marketer's Name & Address
Importer's Name & Address

Description

Learn More about the Book

The past 10 years have seen a remarkable change in the approach to cardiac arrhythmias, from a position of confidence and a feeling of well-being about pharmacological treatment to a situation in which there is now marked uncertainty and general apprehension about the role of antiarrhythmic drugs. Until relatively recently the prevailing concept in antiarrhythmic therapy was that arrhythmias could be controlled by drugs which slowed conduction or suppressed automaticity, goals well served by the sodium channel-blocking drugs and glycosides. Drug re search was based largely on the development of agents mimicking those already available, but with greater efficacy, fewer side effects or a more favourable phar macokinetic profile. The CAST trial stands out as a landmark in the evolution of arrhytmia manage ment; rarely has a single trial had such a profound impact not only on clinical prac tice, but also on the whole approach of those involved in the research, development and regulation of antiarrhythmic drugs. The results of the CAST trial, designed to redress the shortcomings of earlier trials which had failed to demonstrate the anticipated improvement in mortality post-myocardial infarction with the use of class I agents, are well known. The CAST and CAST II showed an increase in mor tality associated with the active agent (encainide, flecainide or morizicine) com pared to placebo treatment. They firmly established the potential danger in the use of class I drugs."

On the Back Cover

Management and prevention of tachyarrhythmias, especially of serious ventricular arrhythmias after myocardial infarction, is still a major problem. Large-scale evidence suggests an increased harm induced by antiarrhythmic drugs in the presence of organic heart disease although they effectively suppress spontaneous arrhythmias. This increased risk has been linked to their proarrhythmic potential and to possible interactions by ischaemia. However, the mechanisms by which antiarrhythmic drugs exert their antiarrhythmic and proarrhythmic actions are still poorly understood. Therefore, it was a time to present an update on the mechanisms of antiarrhythmic and proarrhythmic action of drugs which act on the electrophysiological properties of the heart. World renowned electrophysiologists as well as clinicians have joint to address important topics which range from the effect of antiarrhythmic drugs on single channels and on arrhythmia models to the clinical arena.

Terms & Conditions

The images represent actual product though color of the image and product may slightly differ.

Snapdeal does not select, edit, modify, alter, add or supplement the information, description and other specifications provided by the Seller.

Quick links

Ratings & Reviews

  • 2.6/5

    37 Ratings & 0 Review

  • No recommendations yet.
    Would you like to recommend this item? Yes No
  • Have you used this product?

    Review
Rating info is based on overall customer ratings

Questions & Answers

Have a Question?

Get answers from experts and customers who have used this item.

Seller Details

View Store


Expand your business to millions of customers